About the VTE Prophylaxis Toolkit

VTE is a serious and common complication for patients in hospital or undergoing surgery. Evidence shows that the incidence of VTE can be substantially reduced or prevented by providing appropriate, evidence-based thromboprophylaxis interventions. In Canada, we currently use the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) as the accepted standard of practice for the prevention of VTE. (Geerts WH, et al. Chest 2008; 133:381S-453S)

Please note: You must be a registered user to view most links on this site. Click here to register or login.

The material in this kit has been developed by Canadian thrombosis experts based on the ACCP Guidelines and best practices for the prevention of venous thromboembolism within hospitals and health authorities from across Canada.

This package contains a sample clinical order-set, audit, education and implementation material. We developed this material to address specific questions regarding the use of tinzaparin for VTE prophylaxis such as appropriate use of thromboprophylaxis, weight-based vs. fixed dosing, appropriate dosing for under- and over-weight patients, and dosing in patients with renal impairment or on hemodialysis. In making our recommendations we reviewed the available literature and consulted with Canadian experts who have a significant amount of experience with LMWH and tinzaparin in particular.



Copyright 2019 VTE Simplified.   Disclaimer and Privacy Policy   Grant in aid from Leo Pharma Inc.

Back to Top